Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction

Matthias Schwenkglenks; Toby J Toward; Stephanie Plent; Thomas D Szucs; Daniel J Blackman; Andreas Baumbach

doi:10.1136/heartjnl-2011-301323

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction

Matthias Schwenkglenks, Toby J Toward, Stephanie Plent, Thomas D Szucs, Daniel J Blackman, Andreas Baumbach

Bristol Medical School (THS)

Research output: Contribution to journal › Article (Academic Journal) › peer-review

27 Citations (Scopus)

Abstract

To assess the cost-effectiveness of bivalirudin versus heparin and glycoprotein IIb/IIIa inhibitor (H-GPI) in patients undergoing primary percutaneous coronary intervention (PPCI) for acute ST-segment elevation myocardial infarction (STEMI), from a UK health service perspective.

Original language	English
Pages (from-to)	544-51
Number of pages	8
Journal	Heart
Volume	98
DOIs	https://doi.org/10.1136/heartjnl-2011-301323
Publication status	Published - 2012

Keywords

Aged
Anticoagulants
Cost-Benefit Analysis
Drug Therapy, Combination
Electrocardiography
Female
Follow-Up Studies
Heparin
Hirudins
Humans
Male
Middle Aged
Myocardial Infarction
Peptide Fragments
Platelet Glycoprotein GPIIb-IIIa Complex
Quality-Adjusted Life Years
Recombinant Proteins
Retrospective Studies
Time Factors
Treatment Outcome

Access to Document

10.1136/heartjnl-2011-301323

Handle.net

Persistent link

Cite this

@article{aeed70ca24d942c8862255ea298cdff6,

title = "Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction",

abstract = "To assess the cost-effectiveness of bivalirudin versus heparin and glycoprotein IIb/IIIa inhibitor (H-GPI) in patients undergoing primary percutaneous coronary intervention (PPCI) for acute ST-segment elevation myocardial infarction (STEMI), from a UK health service perspective.",

keywords = "Aged, Anticoagulants, Cost-Benefit Analysis, Drug Therapy, Combination, Electrocardiography, Female, Follow-Up Studies, Heparin, Hirudins, Humans, Male, Middle Aged, Myocardial Infarction, Peptide Fragments, Platelet Glycoprotein GPIIb-IIIa Complex, Quality-Adjusted Life Years, Recombinant Proteins, Retrospective Studies, Time Factors, Treatment Outcome",

author = "Matthias Schwenkglenks and Toward, {Toby J} and Stephanie Plent and Szucs, {Thomas D} and Blackman, {Daniel J} and Andreas Baumbach",

year = "2012",

doi = "10.1136/heartjnl-2011-301323",

language = "English",

volume = "98",

pages = "544--51",

journal = "Heart",

issn = "1355-6037",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction

AU - Schwenkglenks, Matthias

AU - Toward, Toby J

AU - Plent, Stephanie

AU - Szucs, Thomas D

AU - Blackman, Daniel J

AU - Baumbach, Andreas

PY - 2012

Y1 - 2012

N2 - To assess the cost-effectiveness of bivalirudin versus heparin and glycoprotein IIb/IIIa inhibitor (H-GPI) in patients undergoing primary percutaneous coronary intervention (PPCI) for acute ST-segment elevation myocardial infarction (STEMI), from a UK health service perspective.

AB - To assess the cost-effectiveness of bivalirudin versus heparin and glycoprotein IIb/IIIa inhibitor (H-GPI) in patients undergoing primary percutaneous coronary intervention (PPCI) for acute ST-segment elevation myocardial infarction (STEMI), from a UK health service perspective.

KW - Aged

KW - Anticoagulants

KW - Cost-Benefit Analysis

KW - Drug Therapy, Combination

KW - Electrocardiography

KW - Female

KW - Follow-Up Studies

KW - Heparin

KW - Hirudins

KW - Humans

KW - Male

KW - Middle Aged

KW - Myocardial Infarction

KW - Peptide Fragments

KW - Platelet Glycoprotein GPIIb-IIIa Complex

KW - Quality-Adjusted Life Years

KW - Recombinant Proteins

KW - Retrospective Studies

KW - Time Factors

KW - Treatment Outcome

UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-84858619185&partnerID=8YFLogxK

U2 - 10.1136/heartjnl-2011-301323

DO - 10.1136/heartjnl-2011-301323

M3 - Article (Academic Journal)

C2 - 22313548

VL - 98

SP - 544

EP - 551

JO - Heart

JF - Heart

SN - 1355-6037

ER -

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction

Abstract

Keywords

Access to Document

Handle.net

Other files and links

Fingerprint

Cite this